Outcome Instruments in Practice and Baseline Underreporting in Untreated CSU

Chronic spontaneous urticaria is assessed through several validated instruments that measure distinct but related dimensions of disease: the daily UAS and UAS7 quantify objective disease activity through hive count and itch severity; the Urticaria Control Test (UCT) captures the patient's own perception of disease control; and the Dermatology Life Quality Index (DLQI) measures the broader impact of disease on daily functioning. The updated international guidelines recommend UAS7 and UCT as primary monitoring tools for CSU, with provocation thresholds added for inducible subtypes. In clinical practice, however, implementing a multi-instrument assessment consistently across a busy practice requires deliberate workflow integration, and not all instruments are equally accessible or practical in every clinical setting.

A recurring pattern across multiple CSU data sets — including the REMIX-1/-2 remibrutinib analyses — is that the correlation between UAS7 and UCT is moderate at baseline but strengthens substantially once effective treatment is underway. This dynamic reflects a clinically important phenomenon: patients who have lived with poorly controlled CSU for months or years may lack a meaningful reference point for what disease control actually feels like, and as a result may underreport the degree to which their disease is affecting them at the time of initial evaluation. The implication is that pre-treatment severity assessments, while necessary, may systematically underestimate true disease burden — and that the full impact of untreated CSU may only become legible to both patient and clinician retrospectively, once effective therapy has established a new baseline for comparison.

In this final segment of the video discussion on CSU management updates, Steve Dorman, MD, notes that this underreporting dynamic has direct implications for escalation decisions: a patient whose baseline UCT or UAS7 appears only moderately abnormal may in fact be carrying a heavier burden than the scores reflect, and clinicians should weigh that possibility when deciding whether to advance therapy. Eric Karlin, MD, adds that in his practice he captures both UAS7 and UCT routinely, finding that the 2 instruments together provide a more complete picture than either alone — and that watching the UCT rise in parallel with falling UAS7 scores as treatment takes effect is itself one of the more reliable signals that a step-up therapy is producing genuine disease control rather than partial or transient relief.